CCRM
Mohad Mehrabian, PhD, has a diverse academic and professional background in the field of biotechnology and neuroscience. With experience ranging from postdoctoral work at esteemed institutions like University of California, San Francisco and University of Toronto, to receiving prestigious scholarships and awards, Mehrabian has demonstrated a strong commitment to academic excellence and research in neurodegenerative diseases. Currently serving as the Manager of Technology and Venture Development at CCRM, Mehrabian continues to contribute to the advancement of science and technology in the industry.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.